Early data shows mRNA-4359 may benefit patients with advanced solid cancers

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

World’s first comparative study shows safety of single-port robotic thymectomy

A Joint research team (Prof. Jun-hee Lee, Hyun-koo Kim, Jin-Wook Hwang, Jae-Ho Chung, the Department of Thoracic and Cardiovascular Surgery, Korea University College of Medicine)

November 6, 2024

Vutrisiran shows potential to become the new standard of care for rare heart disease

Vutrisiran significantly improved mortality, cardiovascular events and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research presented in

August 30, 2024

DOUGLAS Group raises sales forecast for the financial year 2023/24 and sells online pharmacy Disapo – Biotech Investments

EQS-News: Douglas AG / Key word(s): Development of Sales DOUGLAS Group raises sales forecast for the financial year 2023/24 and sells online pharmacy Disapo 17.07.2024

July 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.